HRTX

HERON THERAPEUTICS, INC. /DE/

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0000818033
$0.4000 -2.44% $75.7M
High Impact Filing (7/10)6 New Institutional Positions4 Institutional Exits
Vol
Market Cap$75.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders50 funds
Inst. Value$53.9M
Inst. Activity6 buys / 4 sells
SEC Reports7
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0000818033·Prev Close $0.4100

Recent Activity

Jun 6, 2026 Insider
Forbes William P acquired via exercise 12,500 shares
EVP, Chief Development Officer
Jun 5, 2026 short_volume
Short Volume: HRTX — 55.3% short (1.4M / 2.5M)
Short: 1,395,273 | Exempt: 42,707 | TRF Vol: 2,525,051 | Short Ratio: 55.3% | Off-exchange volume (d
Jun 2, 2026 SEC
The U.S. District Court for the District of Delaware held that the asserted claims of Heron's CINVANTI patents (U.S. Pat
8-K — Impact 7/10
May 11, 2026 SEC
Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8.1M ($-0.04/share) v
PRESS-RELEASE — Impact 6/10
May 11, 2026 SEC
Heron Therapeutics reported Q1 2026 total net revenue of $34.7M, a 10.8% YoY decline from $38.9M, driven by a 26.3% drop
8-K — Impact 6/10
May 6, 2026 Insider
Hensley Mark Earl acquired via exercise 125,000 shares
Chief Operating Officer
Apr 30, 2026 Insider
Collard Craig A acquired via exercise 34,789 shares
Chief Executive Officer
Inst.
PANAGORA ASSET MANAGEMENT INC — DOUBLED
962,505 shares ($770.1K)

Price Targets

$3.00 +649.8% upside Strong Buy
Current $0.4001 Low $2.00 Median $3.00 High $4.00 2 analysts
$2.00 $4.00

Analyst Ratings

Strong Buy89% buy · 9 analysts
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 3, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Jun 3, 2026 Needham DOWNGRADE Buy → Hold
Jan 9, 2026 HC Wainwright & Co. REITERATE Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.02 ▼ -100.0% $-0.02 — $-0.02 0% YoY 1
Next Q $-0.02 $-0.02 — $-0.02 45% YoY 1
Current FY $-0.09 ▼ -200.0% $-0.09 — $-0.09 -69% YoY 1

Latest Reports

BEARISH 8-K 7/10
The U.S. District Court for the District of Delaware held that the asserted claims of Heron's CINVANTI patents (U.S. Pat
Jun 2, 2026
BEARISH PRESS-RELEASE 6/10
Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8.1M ($-0.04/share) v
May 11, 2026

Top Institutional Holders

FundValueMove
ROYAL BANK OF CANADA—ADD
Rubric Capital Management LP$24.0M—
BlackRock, Inc.$8.1M—
VANGUARD CAPITAL MANAGEMENT LLC$6.2M—
STATE STREET CORP$3.1M—

Recent Insider Trades

DateInsiderTypeValue
Jun 6, 2026Forbes WilliamM$0.00
May 6, 2026Hensley MarkM$0.00
Apr 30, 2026Collard CraigM$0.00
Apr 30, 2026Duarte IraM$0.00
Apr 30, 2026Forbes WilliamM$0.00
50 institutional holders with $53.9M total value (67,305,988 shares) as of 2026-Q1. Top holders: ROYAL, Rubric, BlackRock,. Net buying activity: 6 institutions added/increased vs 4 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1ROYAL BANK OF CANADA143$0.000.0%ADD +47.1%
2Rubric Capital Management LP30,046,828$24.0M44.6%—
3BlackRock, Inc.10,106,422$8.1M15.0%—
4VANGUARD CAPITAL MANAGEMENT LLC7,810,329$6.2M11.6%—
5STATE STREET CORP3,843,672$3.1M5.7%—
6D. E. Shaw & Co., Inc.2,600,990$2.1M3.9%—
7RENAISSANCE TECHNOLOGIES LLC1,718,300$1.4M2.5%TRIM -32.9%
8CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,376,367$1.1M2.0%—
9VANGUARD PORTFOLIO MANAGEMENT LLC1,309,312$1.0M1.9%—
10VANGUARD FIDUCIARY TRUST CO1,152,714$922.2K1.7%—
11GOLDMAN SACHS GROUP INC1,056,944$845.7K1.6%—
12PANAGORA ASSET MANAGEMENT INC962,505$770.1K1.4%DOUBLED +118.6%
13CITADEL ADVISORS LLC759,269$607.5K1.1%—
14Nuveen, LLC526,293$421.1K0.8%ADD +51.6%
15MORGAN STANLEY513,413$410.8K0.8%TRIM -46.7%
16Universal- Beteiligungs- und Servicegesellschaft mbH458,766$367.1K0.7%—
17Invesco Ltd.326,512$261.2K0.5%ADD +33.0%
18ALLIANCEBERNSTEIN L.P.198,550$258.1K0.5%—
19TWO SIGMA INVESTMENTS, LP317,400$254.0K0.5%ADD +44.4%
20SUSQUEHANNA INTERNATIONAL GROUP, LLP288,253$230.6K0.4%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
PANAGORA ASSET MANAGEMENT INCDOUBLED440,252962,505+118.6%$770.1K2026-Q1
Nuveen, LLCADD347,065526,293+51.6%$421.1K2026-Q1
MORGAN STANLEYTRIM963,851513,413-46.7%$410.8K2026-Q1
GROUP ONE TRADING LLCTRIM145,16786,809-40.2%$69.5K2026-Q1
FMR LLCTRIM84,19758,195-30.9%$46.6K2026-Q1
Mariner, LLCADD18,99935,353+86.1%$28.3K2026-Q1
CWM, LLCDOUBLED10,62828,890+171.8%$23.1K2026-Q1
Rockefeller Capital Management L.P.DOUBLED4151,286+209.9%$1.0K2026-Q1
PRICE T ROWE ASSOCIATES INC /MD/ADD76,638111,504+45.5%$90.002026-Q1
ADAGE CAPITAL PARTNERS GP, L.L.C.EXIT11,185,3250-100.0%$0.002026-Q1
RENAISSANCE TECHNOLOGIES LLCTRIM2,854,9991,915,900-32.9%$2.5M2025-Q4
TWO SIGMA INVESTMENTS, LPADD692,279999,509+44.4%$1.3M2025-Q4
MORGAN STANLEYTRIM2,468,041963,851-60.9%$1.3M2025-Q4
Invesco Ltd.ADD231,395307,861+33.0%$400.2K2025-Q4
WELLS FARGO & COMPANY/MNADD123,132179,620+45.9%$233.5K2025-Q4
BANK OF AMERICA CORP /DE/NEAR_EXIT732,073134,445-81.6%$174.8K2025-Q4
FMR LLCADD47,39484,197+77.7%$109.5K2025-Q4
Mariner, LLCTRIM35,89918,999-47.1%$24.7K2025-Q4
Cerity Partners LLCTRIM51,71217,063-67.0%$22.2K2025-Q4
Russell Investments Group, Ltd.TRIM17,21812,671-26.4%$16.5K2025-Q4
Allworth Financial LPDOUBLED1,5549,329+500.3%$12.1K2025-Q4
Rockefeller Capital Management L.P.DOUBLED61415+580.3%$539.002025-Q4
CWM, LLCNEAR_EXIT45,01510,628-76.4%$14.002025-Q4
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD7,852,00010,239,225+30.4%$12.9M2025-Q3
MARSHALL WACE, LLPTRIM2,894,0721,308,861-54.8%$1.6M2025-Q3
10 unique insiders with 27 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 6, 2026Forbes William PEVP, Chief Development OfficerEXERCISE12,500——
May 6, 2026Hensley Mark EarlChief Operating OfficerEXERCISE125,000——
Apr 30, 2026Collard Craig AChief Executive OfficerEXERCISE34,789——
Apr 30, 2026Duarte IraEVP, Chief Financial OfficerEXERCISE11,694——
Apr 30, 2026Forbes William PEVP, Chief Development OfficerEXERCISE11,694——
Apr 30, 2026Hensley Mark EarlChief Operating OfficerEXERCISE11,770——
Apr 19, 2026Collard Craig AChief Executive OfficerEXERCISE13,797——
Apr 19, 2026Duarte IraEVP, Chief Financial OfficerEXERCISE3,874——
Apr 19, 2026Forbes William PEVP, Chief Development OfficerEXERCISE3,874——
Apr 3, 2026Collard Craig AChief Executive OfficerEXERCISE62,500——
Jan 31, 2026Duarte IraEVP, Chief Financial OfficerEXERCISE11,695——
Jan 31, 2026Forbes William PEVP, Chief Development OfficerEXERCISE11,695——
Jan 31, 2026Collard Craig AChief Executive OfficerEXERCISE34,789——
Jan 30, 2026Collard Craig AChief Executive OfficerAWARD800,337——
Jan 30, 2026Collard Craig AChief Executive OfficerAWARD800,336——
Jan 30, 2026Christian WaageDirectorAWARD53,960——
Jan 30, 2026Kaseta MichaelDirectorAWARD53,960——
Jan 30, 2026Duarte IraEVP, Chief Financial OfficerAWARD216,562——
Jan 30, 2026Duarte IraEVP, Chief Financial OfficerAWARD216,561——
Jan 30, 2026Johnson Craig ADirectorAWARD53,960——
Jan 30, 2026Cusack ThomasDirectorAWARD53,960——
Jan 30, 2026Forbes William PEVP, Chief Development OfficerAWARD188,315——
Jan 30, 2026Forbes William PEVP, Chief Development OfficerAWARD188,314——
Jan 30, 2026Dissanaike SharmilaDirectorAWARD53,960——
Jan 30, 2026Hensley Mark EarlChief Operating OfficerAWARD188,315——
Jan 30, 2026Hensley Mark EarlChief Operating OfficerAWARD188,314——
Jan 30, 2026Morgan AdamDirectorAWARD53,960——
7 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 1 mixed, 3 neutral. Avg impact: 4.6/10.
BEARISH 8-K 7/10
The U.S. District Court for the District of Delaware held that the asserted claims of Heron's CINVAN
Jun 2, 2026
BEARISH PRESS-RELEASE 6/10
Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8
May 11, 2026
BEARISH 8-K 6/10
Heron Therapeutics reported Q1 2026 total net revenue of $34.7M, a 10.8% YoY decline from $38.9M, dr
May 11, 2026
NEUTRAL DEFA14A 2/10
Heron Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting scheduled
Apr 30, 2026
NEUTRAL PRESS-RELEASE 1/10
Heron Therapeutics announced it will report Q1 2026 financial results on May 11, 2026. No financial
Apr 27, 2026
NEUTRAL 8-K 4/10
Heron Therapeutics amended and restated employment agreements with CEO Craig Collard and three other
Apr 6, 2026
MIXED 8-K 6/10
Heron Therapeutics reported full-year 2025 net revenue of $154.9 million, up 7.4% year-over-year, dr
Feb 26, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$3.00 mean target +649.8% upside Strong Buy (1.67)
$2.00 Low $4.00 High
MetricValue
Current Price$0.4001
Target Low$2.00
Target Mean$3.00
Target Median$3.00
Target High$4.00
# Analysts2
RecommendationStrong Buy (1.67)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.02 $-0.02 $-0.02 0.0% -100.0% — $0.0B 13.3% 1
Next Q
2026-09-30
 $-0.02 $-0.02 $-0.02 44.6% — — $0.0B 12.9% 1
Current FY
2026-12-31
 $-0.09 $-0.09 $-0.09 -69.5% -200.0% 1↑ 0↓ $0.2B 6.9% 1
Next FY
2027-12-31
 $0.00 $0.00 $0.00 100.0% — 1↑ 0↓ $0.2B 6.2% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.020
7d ago$-0.020
30d ago$-0.010-0.010
60d ago$-0.010-0.010
90d ago$-0.010-0.010
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 3, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Jun 3, 2026 Needham DOWNGRADE Buy Hold
Jan 9, 2026 HC Wainwright & Co. REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20262610089%
May 1, 20262610089%
Apr 1, 20262610089%
Mar 1, 20262610089%
Feb 1, 20263610090%
Jan 1, 20263610090%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 10, 2026
Clinical Trial
Dose-Escalation Study of HTX-034 Following Bunionectomy
Phase Phase 2 — COMPLETED
Jun 5, 2026
short_volume
Short Volume: HRTX — 55.3% short (1.4M / 2.5M)
Short: 1,395,273 | Exempt: 42,707 | TRF Vol: 2,525,051 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
Clinical Trial
Study of Post-Herniorrhaphy Non-opioid MMA Regimens
Phase Phase 3 — COMPLETED
Jun 3, 2026
short_volume
Short Volume: HRTX — 72.7% short (5.4M / 7.4M)
Short: 5,403,850 | Exempt: 601,531 | TRF Vol: 7,428,547 | Short Ratio: 72.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
other
U.S. District Court Issues Decision Regarding CINVANTI® Patents
After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal <pre>After Reviewing the Ruling, Heron Belie
Jun 2, 2026
short_volume
Short Volume: HRTX — 68.6% short (9.8M / 14.3M)
Short: 9,839,203 | Exempt: 1,030,645 | TRF Vol: 14,342,745 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: HRTX — 56.8% short (0.6M / 1.1M)
Short: 598,269 | Exempt: 28,640 | TRF Vol: 1,053,985 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: HRTX — 57.3% short (0.6M / 1.1M)
Short: 616,780 | Exempt: 424 | TRF Vol: 1,077,281 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: HRTX — 56.8% short (0.6M / 1.0M)
Short: 578,322 | Exempt: 0 | TRF Vol: 1,018,937 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: HRTX — 63.4% short (0.8M / 1.2M)
Short: 760,990 | Exempt: 633 | TRF Vol: 1,200,798 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: HRTX — 55.1% short (0.6M / 1.2M)
Short: 646,727 | Exempt: 0 | TRF Vol: 1,172,933 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 12, 2026
Clinical Trial
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Phase Phase 2 — COMPLETED
May 11, 2026
earnings
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
<p align="justify">CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-st
May 11, 2026
earnings_calendar
HRTX Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: HRTX — 58.6% short (2.9M / 4.9M)
Short: 2,869,418 | Exempt: 329,031 | TRF Vol: 4,895,612 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: HRTX — 59.6% short (0.5M / 0.8M)
Short: 491,237 | Exempt: 12,700 | TRF Vol: 823,633 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: HRTX — 67.0% short (0.4M / 0.7M)
Short: 444,876 | Exempt: 281 | TRF Vol: 664,472 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
HRTX Q1 2026 Earnings Scheduled — 2026-05-04
Apr 1, 2026
Clinical Trial
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Phase Phase 2 — TERMINATED